News

2016

company

year

domain

Seres Therapeutics Announces Publication of Positive SER-109 Phase 1b/2 Study Results in The Journal of Infectious Diseases

Seres Therapeutics 02.09.2016

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

Editas Medicine 02.08.2016

Editas Medicine Announces Pricing of Initial Public Offering

Editas Medicine 02.03.2016

Editas Medicine Appoints John D. Mendlein, Ph.D., to Board of Directors

Editas Medicine 01.29.2016

Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., as Chief Medical Officer

01.27.2016

Quanterix Announces Expansion into Asia Pacific

Quanterix 01.27.2016

Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics

01.27.2016

Black Duck’s 2015 Growth Spurs Major Expansion at Burlington Headquarters

Black Duck Software 01.27.2016

BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

BIND Therapeutics 01.27.2016

Codiak BioSciences Closes $61 Million Series B Financing

01.26.2016

Loading